StockNews.AI
BLRX
StockNews.AI
84 days

BioLineRx Reports First Quarter 2025 Financial Results and Provides Corporate Update

1. BioLineRx reported progress in oncology and rare disease asset evaluations. 2. Positive interim results from the CheMo4METPANC Phase 2b trial on motixafortide. 3. APHEXDA shows strong performance under Ayrmid, expected to add long-term value. 4. The company successfully reduced operating expenses by over 70% since January 2025. 5. BioLineRx has cash runway confirmed through late 2026.

Earnings
+1.09%Current Return
VS
+1.91%S&P 500
$3.6605/27 07:07 AM EDTEvent Start
$3.705/28 01:28 PM EDTLatest Updated
29m saved
Insight
Article

FAQ

Why Bullish?

The developments in clinical trials and reduced operating costs indicate improved financial health and growth potential, similar to past successful product launches boosting stock prices.

How important is it?

The article's focus on BLRX's reduced expenses, ongoing clinical trials, and potential new transactions significantly affect investor outlook.

Why Long Term?

The long-term value addition from APHEXDA and ongoing clinical trials suggest sustained growth potential beyond upcoming fiscal quarters.

Related Companies

AYRGLBS
- Reports continued progress in the evaluation of assets for potential in-licensing and development in the areas of oncology and rare disease - - New data from pilot phase of ongoing CheMo4METPANC Phase 2b combination trial of motixafortide in PDAC, sponsored by Columbia University, to be presented at upcoming 2025 ASCO Annual Meeting – - APHEXDA performing well under Ayrmid stewardship - - Management to host conference call today, May 27th, at 8:30 am EDT - , /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a development stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today reported its unaudited financial results for the quarter ended March 31, 2025, and provided a corporate update. "Following our announcement last November that we out-licensed APHEXDA®, our FDA-approved stem cell mobilization agent, to Ayrmid Ltd., we have been actively evaluating new assets in the areas of oncology and rare disease where we can leverage our drug development and regulatory expertise to bring new medicines to market," said Philip Serlin, Chief Executive Officer of BioLineRx. "I remain optimistic that we will announce a meaningful transaction this year." "At the same time, APHEXDA is performing well under the stewardship of Ayrmid, and I believe this license agreement will contribute significant long-term value to our company," Mr. Serlin concluded.   Financial Updates Completed financing in January 2025 raising gross proceeds of $10 million. Successfully reduced operating expense run rate by over 70% beginning January 1, 2025, through the APHEXDA program transfer to Ayrmid and the resulting shutdown of the Company's U.S. commercial operations in Q4 2024, as well as additional headcount and other operating expense reductions. Reaffirms cash runway through the second half of 2026. APHEXDA Performance Update APHEXDA generated sales of $1.4 million in the first quarter of 2025, providing royalty revenues to the Company of $0.3 million. Clinical Updates Motixafortide Pancreatic Ductal Adenocarcinoma (mPDAC) Additional trial sites were activated for the CheMo4METPANC Phase 2b clinical trial, which is expected to have a positive impact on patient recruitment. Full enrollment in the randomized trial, which is being led by Columbia University, and supported by both Regeneron and BioLineRx, is planned for completion in 2027, with a prespecified interim analysis planned when 40% of progression free survival (PFS) events are observed. An abstract featuring updated data from the pilot phase of the ongoing CheMo4METPANC clinical trial has been accepted for a poster presentation at the 2025 ASCO Annual Meeting on Saturday, May 31st. Key highlights include:   Two patients underwent definitive treatment for metastatic pancreatic cancer: one had complete resolution of all radiologically detected liver lesions and underwent definitive radiation to the primary pancreatic tumor, and one had a sustained partial response and underwent pancreaticoduodenectomy with pathology demonstrating a complete response. An analysis of pre- and on-treatment biopsies revealed that CD8+ T-cell tumor infiltration increased across all eleven patients treated with the motixafortide combination. Sickle Cell Disease (SCD) & Gene Therapy Enrollment is continuing into the multi-center Phase 1 clinical trial evaluating motixafortide for the mobilization of CD34+ hematopoietic stem cells (HSCs) used in the development of gene therapies for patients with Sickle Cell Disease (SCD). The trial is sponsored by St. Jude Children's Research Hospital. Reported continued progress of a Phase 1 clinical trial evaluating motixafortide as monotherapy and in combination with natalizumab for stem cell mobilization for gene therapies in sickle cell disease. The trial is sponsored by Washington University School of Medicine in St. Louis. Financial Results for the Quarter Ended March 31, 2025 Revenues for the three-month period ended March 31, 2025 were $0.3 million, a decrease of $6.6 million, compared to revenues of $6.9 million for the three-month period ended March 31, 2024. The significant decrease in revenues from 2024 to 2025 reflects the one-time revenues recorded in 2024 relating to the out-licensing transaction with Gloria during the fourth quarter of 2023, as well as the change in the Company's operations following the out-licensing of APHEXDA to Ayrmid during the fourth quarter of 2024. The revenues in 2025 reflect the royalties paid by Ayrmid from the commercialization of APHEXDA in stem cell mobilization in the U.S. The revenues in 2024 primarily reflect a portion of the up-front payment received by the Company and a milestone payment achieved under the license agreement with Gloria, which collectively amounted to $5.9 million, as well as $0.9 million of net revenues from product sales of APHEXDA in the U.S. Cost of revenues for the three-month period ended March 31, 2025 was immaterial, compared to cost of revenues of $1.5 million for the three-month period ended March 31, 2024. The cost of revenues in 2025 reflects sub-license fees on royalties paid by Ayrmid from the commercialization of APHEXDA in stem cell mobilization in the U.S. The cost of revenues in 2024 primarily reflects sub-license fees on a milestone payment received under the Gloria license agreement and royalties on net product sales of APHEXDA in the U.S., as well as amortization of intangible assets and cost of goods sold on product sales. Research and development expenses for the three months ended March 31, 2025 were $1.6 million, a decrease of $0.9 million, or 34.9%, compared to $2.5 million for the three months ended March 31, 2024. The decrease resulted primarily from lower expenses related to motixafortide due to the out-licensing of U.S. rights to Ayrmid, as well as a decrease in payroll and share-based compensation, primarily due to a decrease in headcount. There were no sales and marketing expenses for the three months ended March 31, 2025, compared to $6.3 million for the three months ended March 31, 2024. The decrease resulted primarily from the shutdown of U.S. commercial operations in the fourth quarter of 2024 following the Ayrmid out-licensing transaction. General and administrative expenses for the three months ended March 31, 2025 were $1.0 million, a decrease of $0.4 million, or 28.6%, compared to $1.4 million for the three months ended March 31, 2024. The decrease resulted primarily from a decrease in payroll and share-based compensation, primarily due to a decrease in headcount, as well as small decreases in a number of general and administrative expenses. Net non-operating income for the three months ended March 31, 2025 was $7.6 million, compared to net non-operating income of $4.5 million for the three months ended March 31, 2024. Non-operating income for both periods primarily relates to fair-value adjustments of warrant liabilities on the balance sheet, as a result of changes in the Company's share price. Net financial expenses for the three months ended March 31, 2025 were $0.1 million, compared to net financial expenses of $0.4 million for the three months ended March 31, 2024. Net financial expenses for both periods primarily relate to loan interest paid, partially offset by investment income earned on bank deposits. Net income for the quarter ended March 31, 2025 was $5.1 million, compared to $0.7 million for the quarter ended March 31, 2024. As of March 31, 2025, the Company had cash, cash equivalents, and short-term bank deposits of $26.4 million Conference Call and Webcast Information To access the conference call, please dial +1-888-281-1167 from the U.S. or +972-3-918-0685 internationally. A live webcast and a replay of the call can be accessed through the event page on the Company's website. Please allow extra time prior to the call to visit the site and download any necessary software to listen to the live broadcast. The call replay will be available approximately two hours after completion of the live conference call. A dial-in replay of the call will be available until May 29, 2025; please dial +1-888-295-2634 from the US or +972-3-925-5904 internationally. About BioLineRx BioLineRx Ltd. (NASDAQ/TASE: BLRX) is a biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases. The Company's first approved product is APHEXDA® (motixafortide), with an indication in the U.S. for stem cell mobilization for autologous transplantation in multiple myeloma, which is being developed and commercialized by Ayrmid Ltd. (globally, excluding Asia) and Gloria Biosciences (in Asia). BioLineRx is utilizing its end-to-end expertise in development, regulatory affairs and manufacturing to advance its innovative pipeline and ensure life-changing discoveries move beyond the bench to the bedside. Learn more about who we are, what we do, and how we do it at www.biolinerx.com, or on Twitter and LinkedIn.   Forward Looking Statement Various statements in this release concerning BioLineRx's future expectations constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include words such as "anticipates," "believes," "could," "estimates," "expects," "intends," "may," "plans," "potential," "predicts," "projects," "should," "will," and "would," and describe opinions about future events. These include statements regarding management's expectations, beliefs and intentions regarding, among other things, the potential success of the license agreement with Ayrmid and the commercial potential of motixafortide, expectations with regard to clinical trials of motixafortide, the expected cash runway, and BioLineRx's business strategy. These forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of BioLineRx to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Factors that could cause BioLineRx's actual results to differ materially from those expressed or implied in such forward-looking statements include, but are not limited to: the clinical development, commercialization and market acceptance of BioLineRx's therapeutic candidates, including the degree and pace of market uptake of APHEXDA for the mobilization of hematopoietic stem cells for autologous transplantation in multiple myeloma patients; the initiation, timing, progress and results of BioLineRx's preclinical studies, clinical trials, and other therapeutic candidate development efforts; BioLineRx's ability to advance its therapeutic candidates into clinical trials or to successfully complete its preclinical studies or clinical trials, whether the clinical trial results for APHEXDA will be predictive of real-world results; BioLineRx's receipt of regulatory approvals for its therapeutic candidates, and the timing of other regulatory filings and approvals; whether access to APHEXDA is achieved in a commercially viable manner and whether APHEXDA receives adequate reimbursement from third-party payors; BioLineRx's ability to establish, manage, and maintain corporate collaborations, as well as the ability of BioLineRx's collaborators to execute on their development and commercialization plans; BioLineRx's ability to integrate new therapeutic candidates and new personnel as well as new collaborations; the interpretation of the properties and characteristics of BioLineRx's therapeutic candidates and of the results obtained with its therapeutic candidates in preclinical studies or clinical trials; the implementation of BioLineRx's business model and strategic plans for its business and therapeutic candidates; the scope of protection BioLineRx is able to establish and maintain for intellectual property rights covering its therapeutic candidates and its ability to operate its business without infringing the intellectual property rights of others; estimates of BioLineRx's expenses, future revenues, capital requirements and its needs for and ability to access sufficient additional financing; risks related to changes in healthcare laws, rules and regulations in the United States or elsewhere; competitive companies, technologies and BioLineRx's industry; BioLineRx's ability to maintain the listing of its ADSs on Nasdaq; and statements as to the impact of the political and security situation in Israel on BioLineRx's business, which may exacerbate the magnitude of the factors discussed above. These and other factors are more fully discussed in the "Risk Factors" section of BioLineRx's most recent annual report on Form 20-F filed with the Securities and Exchange Commission on March 31, 2025. In addition, any forward-looking statements represent BioLineRx's views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. BioLineRx does not assume any obligation to update any forward-looking statements unless required by law. BioLineRx Ltd. CONDENSED CONSOLIDATED INTERIM STATEMENTS OF FINANCIAL POSITION (UNAUDITED) December 31, March 31, 2024 2025 in USD thousands Assets CURRENT ASSETS Cash and cash equivalents 10,436 9,036 Short-term bank deposits 9,126 17,333 Trade receivables 2,476 1,469 Prepaid expenses 443 312 Other receivables 1,478 452 Inventory 3,145 3,315           Total current assets 27,104 31,917 NON-CURRENT ASSETS Property and equipment, net 386 299 Right-of-use assets, net 967 863 Intangible assets, net 10,449 10,431           Total non-current assets 11,802 11,593           Total assets 38,906 43,510 Liabilities and equity CURRENT LIABILITIES Current maturities of long-term loan 4,479 4,684 Accounts payable and accruals:      Trade 5,583 4,693      Other 3,131 1,751 Current maturities of lease liabilities 522 440 Warrants 1,691 2,462           Total current liabilities 15,406 14,030 NON-CURRENT LIABILITIES Long-term loan, net of current maturities 8,958 7,633 Lease liabilities 1,081 985           Total non-current liabilities 10,039 8,618 COMMITMENTS AND CONTINGENT LIABILITIES      Total liabilities 25,445 22,648 EQUITY Ordinary shares 38,097 62,570 Share premium 353,693 333,627 Warrants 5,367 3,686 Capital reserve 17,547 17,095 Other comprehensive loss (1,416) (1,416) Accumulated deficit (399,827) (394,700)           Total equity 13,461 20,862           Total liabilities and equity 38,906 43,510 BioLineRx Ltd. CONDENSED CONSOLIDATED INTERIM STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (UNAUDITED) Three months ended March 31, 2024 2025 in USD thousands REVENUES:      License revenues 5,931 255      Product sales, net 924 -           Total revenues 6,855 255 COST OF REVENUES (1,455) (34) GROSS PROFIT 5,400 221 RESEARCH AND DEVELOPMENT EXPENSES (2,494) (1,623) SALES AND MARKETING EXPENSES (6,342) - GENERAL AND ADMINISTRATIVE EXPENSES (1,386) (989) OPERATING LOSS (4,822) (2,391) NON-OPERATING INCOME (EXPENSES), NET 4,490 7,644 FINANCIAL INCOME 565 294 FINANCIAL EXPENSES (929) (420) NET INCOME (LOSS) AND COMPREHENSIVE INCOME (LOSS) (696) 5,127 in USD EARNINGS )LOSS( PER ORDINARY SHARE - BASIC AND DILUTED (0.00) 0.00 WEIGHTED AVERAGE NUMBER OF SHARES USED INCALCULATION OF EARNINGS )LOSS( PER ORDINARY SHARE 1,086,589,165 2,217,728,234 BioLineRx Ltd. CONDENSED CONSOLIDATED INTERIM STATEMENTS OF CHANGES IN EQUITY (UNAUDITED) Ordinary shares Share pre-mium Warrants Capital re-serve Other compre-hensive loss Accumulated deficit Total in USD thousands BALANCE AT JANUARY 1, 2024 31,355 355,482 1,408 17,000 (1,416) (390,606) 13,223 CHANGES FOR THREE MONTHS ENDED MARCH 31, 2024: Share-based compensation  - - - 533 - - 533 Comprehensive loss for the period - - - - - (696) (696) BALANCE AT MARCH 31, 2024 31,355 355,482 1,408 17,533 (1,416) (391,302) 13,060 Ordinary shares Share pre-mium Warrants Capital re-serve Other compre-hensive loss Accumulated deficit Total in USD thousands BALANCE AT JANUARY 1, 2025 38,097 353,693 5,367 17,547 (1,416) (399,827) 13,461 CHANGES FOR THREE MONTHS ENDED MARCH 31, 2025: Issuance of share capital, pre-funded warrants and warrants, net 16,415 (14,836) 501 - - - 2,080 Pre-funded warrants exercised 8,058 (5,876) (2,182) - - - - Employee stock options expired - 646 - (646) - - - Share-based compensation  - - - 194 - - 194 Comprehensive income for the period - - - - - 5,127 5,127 BALANCE AT MARCH 31, 2025 62,570 333,627 3,686 17,095 (1,416) (394,700) 20,862 BioLineRx Ltd. CONDENSED CONSOLIDATED INTERIM CASH FLOW STATEMENTS (UNAUDITED) Three months ended March 31, 2024 2025 in USD thousands CASH FLOWS - OPERATING ACTIVITIES Comprehensive income (loss) for the period (696) 5,127 Adjustments required to reflect net cash used in operating activities  (see appendix below) (13,413) (7,718) Net cash used in operating activities (14,109) (2,591) CASH FLOWS - INVESTING ACTIVITIES Investments in short-term deposits  - (12,307) Maturities of short-term deposits 16,719 4,130 Purchase of property and equipment (32) - Net cash provided by (used in) investing activities 16,687 (8,177) CASH FLOWS - FINANCING ACTIVITIES Issuance of share capital, pre-funded warrants and warrants, net of issuance costs - 10,697 Repayments of loan (765) (1,120) Repayments of lease liabilities (129) (127) Net cash provided by (used in) financing activities (894) 9,450 INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS 1,684 (1,318) CASH AND CASH EQUIVALENTS – BEGINNING OF PERIOD            4,255 10,436 EXCHANGE DIFFERENCES ON CASH AND CASH EQUIVALENTS 51 (82) CASH AND CASH EQUIVALENTS - END OF PERIOD 5,990 9,036 BioLineRx Ltd. APPENDIX TO CONDENSED CONSOLIDATED INTERIM CASH FLOW STATEMENTS (UNAUDITED) Three months ended March 31, 2024 2025 in USD thousands Adjustments required to reflect net cash used in operating activities: Income and expenses not involving cash flows: Depreciation and amortization 897 165 Exchange differences on cash and cash equivalents (51) 82 Fair value adjustments of warrants (4,444) (8,311) Warrant issuance costs - 702 Share-based compensation 533 194 Interest on short-term deposits (163) (30) Interest on loan 610 - Exchange differences on lease liabilities  (25) (7) (2,643) (7,205) Changes in operating asset and liability items: Decrease (increase) in trade receivables (2,474) 1,007 Increase in inventory (936) (170) Decrease in prepaid expenses and other receivables 81 1,157 Decrease in accounts payable and accruals (3,511) (2,507) Decrease in contract liabilities (3,930) - (10,770) (513) (13,413) (7,718) Supplemental information on interest received in cash 357 236 Supplemental information on interest paid in cash 255 361 Supplemental information on non-cash transactions:      Changes in right-of-use asset and lease liabilities 32 44      Warrant issuance costs - 237 Logo: https://mma.prnewswire.com/media/2154863/BioLineRx_Ltd_Logo.jpg Contacts: United StatesIrina KofflerLifeSci Advisors, LLC[email protected] IsraelMoran MeirLifeSci Advisors, LLC[email protected] SOURCE BioLineRx Ltd. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In

Related News